Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial
This study provides HRQoL values in a French cohort of CLL patients in consolidation treatment. Supplementation with lenalidomide as consolidation therapy in CLL leads to late health deterioration, especially diarrhea, after 12 months of treatment. Quantitative assessment of HRQoL should be balanced against benefits in disease control to determine overall health benefits.
Authors
- David J. Gottlieb (ORCID: https://orcid.org/0000-0001-5807-1766)
- Florence Cymbalista
- Tienhan Sandrine Dabakuyo‐Yonli (ORCID: https://orcid.org/0000-0002-8191-1222)
- Stephane Kroudia Wasse (ORCID: https://orcid.org/0000-0002-5219-2847)
- Stephen P. Mulligan (ORCID: https://orcid.org/0000-0003-1928-2098)
- Marc Maynadié
- Thérèse Aurran‐Schleinitz
Institutions
- The University of Sydney (AU)
- Inserm (FR)
- Université de Bourgogne (FR)
- Royal North Shore Hospital (AU)
- Westmead Hospital (AU)
- Hôpital Avicenne (FR)
- Institut Paoli-Calmettes (FR)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1186/s12885-025-13792-y
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute